Nir Messafi
@Deep Track Capital, Lp
Latest period2024 - Q3ReportedManaged Assets$3.153BTotal holdings69
Assets growth rate-5.9%Assets growth rate (2-Q avg)-4.96%Continuous growth in asset value0 quarters
Portfolio positions
This chart displays the top 10 holdings in Deep Track Capital, Lp's 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 69 positions.
Assets under management
The assets under management (AUM) of Deep Track Capital, Lp over the past 10 years (40 quarters) show continuous growth in total asset value over the last 0 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 3.153B in assets, with a quarterly growth rate of -5.9% and a 2-quarter average growth rate of -4.96%. The portfolio is managed by Nir Messafi, and others.
Portfolio holdings
Investment | Portfolio % | Reported Value | Recent Activity |
---|---|---|---|
NKTRNektar Therapeutics
| 0.66% | $20.699M 15.923M shares@ $1.31 avg price | Decreased -10.92% |
ETNB89bio Inc
| 0.65% | $20.472M 2.767M shares@ $7.41 avg price | Increased 20.6% |
BCAXBicara Therapeutics Inc
| 0.65% | $20.296M 796,852 shares@ $25.47 avg price | New Position |
AKROAkero Therapeutics Inc
| 0.63% | $19.79M 689,784 shares@ $28.7 avg price | New Position |
FATEFate Therapeutics Inc
| 0.62% | $19.504M 5.573M shares@ $3.51 avg price | |
SLNSilence Therapeutics Plc
| 0.58% | $18.18M 1M shares@ $18.18 avg price | Decreased -26.45% |
ENGNEngene Holdings Inc
| 0.55% | $17.21M 2.608M shares@ $6.61 avg price | Increased 15.9% |
EDITEditas Medicine Inc
| 0.54% | $16.71M 4.9M shares@ $3.42 avg price | Decreased -18.32% |
XNCRXencor Inc
| 0.52% | $16.088M 800,000 shares@ $20.11 avg price | New Position |
PYXSPyxis Oncology Inc
| 0.49% | $15.356M 4.184M shares@ $3.67 avg price |